Financial
FY2025 revenue $642.8m (+5.2%); operating margin -9.5%; net loss $43.5m.
Revenue includes $44.1m patent settlement; underlying revenue fell 2%. No debt.
10x Genomics
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Weak
Customer rating
No reviews yet
Financial health
Band: WeakListed: TXG
FY2025 revenue $642.8m (+5.2%); operating margin -9.5%; net loss $43.5m.
Revenue includes $44.1m patent settlement; underlying revenue fell 2%. No debt.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$642.8m | +5.2% | -US$61m | -US$43.5m | 10x Genomics |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
May 2025: 10x Genomics announced it would lay off 93 workers in Pleasanton, California, amid cost cuts. May 2026: it moved to settle patent litigation with Curio and filed a new patent suit against Element Biosciences, which says it strongly disagrees.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving 10x Genomics found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Life-science research tools supplier; no product recalls, FDA warning letters or clinical safety actions involving 10x Genomics found in HSH's search of the last 24 months.
Contract performance
Aug 2026: 10x Genomics reported Q2 2026 revenue of $151.0m, down from $172.9m a year earlier mainly due to lower patent settlement income, and raised full-year guidance. No notable customer disputes or terminations found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.